vVARDIS Holding AG priced its initial public offering at $18.00 a share on November 13, selling 9,722,223 Class A ordinary shares for roughly $175M in gross proceeds. The price came in three dollars below the bottom of the $21 to $24 range in the prospectus, though the company upsized the deal from 8.33 million shares. Underwriters hold a 30-day option on 1,458,333 more shares.

The Zug company sells Curodont, a peptide treatment for early-stage cavities, and reported $49.68M of revenue in the twelve months ended June 30, 2026 across 153 employees. Most of that comes from Curodont Repair Fluoride Plus, sold in the US as an over-the-counter drug through Henry Schein. A fluoride-free version sells as a medical device in the UK and parts of Europe. Apollo took a stake in April 2026 at a valuation above $1B.

Shares began trading on the NYSE under VVVV on November 13, with closing expected on or about November 16. Goldman Sachs and J.P. Morgan ran the books, joined by William Blair, UBS Investment Bank and Deutsche Bank Securities. The SEC declared the Form F-1 effective on November 12.

Note the regulatory split in the same product line: OTC drug in the US, medical device in Europe. Founders selling a mineralizing or remineralizing claim should expect that fork, and the US drug route does not get you a 510(k) predicate on the other side of the Atlantic.